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ORIGINAL RESEARCH
Body mass index and treatment survival
in patients with RA starting treatment
with TNFα-inhibitors: long-term follow-
up in the real-life METEOR registry
Sytske Anne Bergstra ,1 Cornelia F Allaart,1 David Vega-Morales,2
Marieke De Buck,3 Elizabeth Murphy,4 Karen Salomon Escoto,5
Tom W J Huizinga 1
ABSTRACT
Objectives To study whether there is an association
between body mass index (BMI) category and survival of
various tumour necrosis factor inhibitors (TNFi) in
rheumatoid arthritis (RA) patients in a real-life longitudinal
international registry.
Methods Data from 5230 patients with RA starting
treatment with any TNFi were selected from the METEOR
registry. Patients were divided into six BMI categories: 3.7%
underweight, BMI<18.5 kg/m2; 46% normal weight, BMI
18.5–25 kg/m2; 32% pre-obesity, BMI 25–30 kg/m2; 13%
obesity class I, BMI 30–35 kg/m2; 3.4% obesity class II, BMI
35–40 kg/m2; and 1.6% obesity class III, BMI >40 kg/m2.
Time on treatment in the different BMI categories was
compared for all TNFi combined and for the infliximab,
adalimumab and etanercept separately, using Kaplan–
Meier curves and Cox regression analyses. Cox regression
analyses were adjusted for potential confounders, with
follow-up censored at 5000 days.
Results Patients in obesity class II (HR 1.28, 95% CI 1.06
to 1.54) and III (HR 1.67, 95% CI 1.29 to 2.18) and
underweight patients (HR 1.30, 95% CI 1.07 to 1.58)
showed statistically significantly shorter TNFi survival than
normal weight patients. The effect in underweight patients
was strongest for infliximab (HR 1.82, 95% CI 1.20 to 2.76),
the effect in overweight patients was strongest for infliximab
(category II (HR 1.49, 95% CI 0.98 to 2.26); category III (HR
1.46, 95% CI 0.79 to 2.71)) and etanercept (category II (HR
1.27 95% CI 0.98 to 1.65); category III (HR 1.79, 95% CI
1.25 to 2.55)). No significant effect modification from
reported pain was found.
Conclusion Both underweight and overweight patients
discontinued TNFi treatment earlier than normal weight
patients, without evidence of reported pain as the main
determinant. It remains uncertain what determines TNFi
survival in individual patients.
INTRODUCTION
In the past 30 years, the average body mass
index (BMI) of adults increased globally,
resulting in a worldwide obesity prevalence
of 13% in 2016, which is also reflected in an
increasing number of obese patients with
rheumatoid arthritis (RA).1–3 Since adipose
tissue is known to release mediators of inflam-
mation, obese patients may have increased
levels of inflammatory cytokines such as
To cite: Bergstra SA, Allaart CF,
Vega-Morales D, et al. Body
mass index and treatment
survival in patients with RA
starting treatment with TNFα-
inhibitors: long-term follow-up




► Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/rmdo
pen-2020-001203).
Received 14 February 2020
Revised 9 April 2020
Accepted 14 May 2020
© Author(s) (or their
employer(s)) 2020. Re-use
permitted under CC BY-NC. No
commercial re-use. See rights
and permissions. Published
by BMJ.






What is already known about this subject
► Obese patients may have increased levels of
inflammatory cytokines. It has been hypothesised
that this may lead to a more therapy-resistant state,
resulting in a lower response rate to TNFi for patients
with rheumatoid arthritis (RA) having a high BMI.
What does this study add
► In a real-life observational registry with long-term
follow-up, we found shorter treatment survival on
TNFi for patients with RA who were both underweight
and obese (BMI>30 kg/m2). This effect seemed
strongest for patients from obesity class III
(BMI>40 kg/m2), who showed shorter treatment
survival already early during follow-up. This
association was not related to levels of reported pain,
as has been previously suggested. Furthermore, this is
the first study investigating drug survival for different
TNFi separately. We observed that underweight
patients mainly had a worse response to infliximab,
whereas the relationship between obesity and drug
survival seemed less strong for adalimumab than for
etanercept and infliximab.
How might this impact on clinical practice
► Our data show that in clinical practice, differences in
treatment survival may be expected for patients with
different BMI levels on different TNFi. Moreover,
underweight patients seem to be a neglected group
in research that may require customised treatment.
Whether interventions to stimulate weight loss for
instance could lead to a better treatment response
in obese patients remains to be elucidated.
Rheumatoid arthritis
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tumour necrosis factor α (TNFα), interleukin (IL)-1, IL-6
and MCP-1, which might lead to higher levels of inflam-
mation independently of RA disease activity.4 5 It has been
hypothesised that this may lead to a more therapy-resistant
state.6 7 Several studies have investigated the association
between BMI and disease activity in patients starting TNFα
inhibitors (TNFi), not only in patients with RA but also in
patients with other inflammatory diseases treated with
TNFi, including spondyloarthritis, psoriatic arthritis and
inflammatory bowel disease.8–10 Although the majority of
these studies found a worse treatment response for
patients with higher BMI, results have not been conclusive
and some authors have argued that instead of increased
inflammatory activity, increased pain levels explain the
association between BMI and success of TNFi treatment.11
Furthermore, there is a large heterogeneity between
studies.6 7 11–18 Extreme BMI categories (WHO classifica-
tion criteria19) were rarely included, even though there are
indications that response to TNFi may be especially differ-
ent in patients in the lowest and highest BMI categories.20
Also, follow-up duration in previous studies was usually
less than 1 year. It may be hypothesised that response or
potential failure to treatment with TNFi may be deter-
mined by different mechanisms after longer follow-up
(>1 year) than the direct response to treatment. This
may result in different associations with BMI, which has
not been previously investigated.
Moreover, different studies included different TNFi or
assessed all TNFi as one group, whereas a previous study
suggested that the association between a high BMI and
worse treatment response was stronger for infliximab
than for other TNFi in RA.7
Therefore, we aimed to study the association between
BMI category and primary and delayed drug survival in
patients starting treatment with various TNFi in a real-life
longitudinal registry with several years of follow-up.
METHODS
Data selection
Data from patients with a clinical diagnosis of RA were
included from the METEOR registry. This is an interna-
tional, observational registry capturing patient and disease
characteristics, disease activity, physical functioning and
medication use during daily clinical practice. Patients may
be newly diagnosed, but may also have an existing RA diag-
nosis. Since visits andmeasurementswere scheduled accord-
ing to clinical practice, the total follow-up time and the
frequency of visits differ per patient. Since all data are
anonymised and treatment and measurements are non-
protocolled, medical ethics approval was not required.
A detailed description of the METEOR registry has been
previously published.21
For the current analysis, data were selected from adult
patients with RA starting their first TNFi who had avail-
able data on weight, with at least one visit with an available
composite disease activity measure (disease activity score
28 (DAS28), Simplified Disease Activity Index (SDAI),
Clinical Disease Activity Index (CDAI) or Routine Assess-
ment of Patient Index Data 3), at least 3months follow-up
and available data on start- and end date of medication.
For analyses,TNFi data of the individuals from their first
course of the specific drug were selected.
All available follow-up visits were included, but follow-up
was censored at 5000 days, because after that timepoint,
almost no follow-up data were available. A flow chart of the
patient selection process is depicted in figure 1.
Figure 1 Kaplan–Meier curves for the association between BMI category and drug survival in patients starting TNFi. (A) Data of all
patients starting their first TNFi. Data for patients starting adalimumab (B), etanercept (C) and infliximab (D) are shown separately.
Kaplan–Meier curves are based on non-imputed and non-adjusted data.
BMI, body mass index; TNFi, tumour necrosis factor inhibitor.
RMD Open
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A comparison of included and non-included patients is
described in supplementary file 1.
BMI categories and outcome measures
Patients were divided into six BMI categories according to
the international classification for BMI categories
defined by the WHO: 1) underweight, BMI <18.5 kg/
m2; 2) normal weight, BMI between 18.5 and 24.9 kg/
m2; 3) pre-obesity, BMI between 25.0 and 29.9 kg/m2; 4)
obesity class I, BMI between 30.0 and 34.9 kg/m2; 5)
obesity class II, BMI between 35.0 and 39.9 kg/m2;
and 6) obesity class III, BMI >40.0 kg/m2.22
The primary outcome measure was time on first TNFi
(as proxy for time to treatment failure), which was
defined as the time between the start date and end date
of the first prescribed course of TNFi for each patient.
Secondary outcome measures were the times on the first
prescribed courses of the different types of TNFi: adali-
mumab, certolizumab, etanercept, golimumab and inflix-
imab. If a second course of the same TNFi was started
within 2 months of the first course, this was considered as
one consecutive course, and the total time between the
start date of the first course and the end date of
the second course was calculated.
Statistical analyses
Baseline characteristics were compared between the dif-
ferent BMI categories. Additionally, baseline characteris-
tics were compared between the various TNFi. Kaplan–
Meier curves were drawn to compare unadjusted time on
treatment for the different BMI categories, for all TNFi
combined and for the various TNFi separately.
Missing data were imputed using chained equations (40
imputation cycles) with predictive mean matching (with
five observations to draw from) for continuous variables
and (multinomial) logit regression for categorical vari-
ables. Missing data were imputed for the variables such as
BMI, height, age, symptom duration, DAS28, baseline
DAS28, SDAI, CDAI, Health Assessment Questionnaire,
erythrocyte sedimentation rate (ESR), C reactive protein,
visual analogue scale (VAS) patient and physician global,
28 tender and swollen joint count, gender, rheumatoid
factor, anti-citrullinated protein antibodies and smoking,
based on complete information on weight, treatment,
country, follow-up duration, the total number of pre-
scribed biologicals per patient and date of the first TNFi
prescription. Continuous variables that did not follow
a Gaussian distribution were transformed by taking the
square root.
Subsequently, as primary analysis Cox proportional
hazards regression analyses were performed in the
imputed database to investigate the association between
BMI category and time on treatment, for time on first
TNFi and for time on the first course of the different TNFi
separately. As primary failure (direct non-response) of
a TNFi may occur through different mechanisms than
delayed failure (later loss of response), we performed
secondary analyses, in which we repeated the same ana-
lyses with follow-up time limited to 1 year. All Cox regres-
sion analyses were adjusted for the potential confounders
such as age, gender, smoking (yes, no, quit smoking,
defined at entry in the registry), baseline DAS28 and
concomitant glucocorticoid use. All potential confoun-
ders were selected based on current literature and expert
knowledge.11 12 16 18 Additionally, it was tested whether
adjusting for country of residence influenced the results.
However, as this did not influence any of the outcomes,
these results are not presented.
In addition, since patients with a high BMI are
described to report more pain, it was assessed whether
the association between BMI and time on treatment was
similar for patients with similar levels of pain at
baseline.11 23–26 For this, potential effect modification
by pain category (VAS pain between 0 and 25, 25 and 50,
50 and 75, and 75 and 100) was tested by adding an
interaction term between BMI category and pain cate-
gory. Lastly, we performed linear regression analyses to
investigate the association between BMI category and
DAS at the final available visit before stopping the
TNFi, to investigate whether the decision to stop treat-
ment was made at different disease activity levels. All
analyses were performed using Stata SE version 14 (Sta-
taCorp LP) and p values <0.05 were considered statisti-
cally significant.
Patient and public involvement
Patient and public were not involved in design, conduct,
reporting or dissemination of the research.
RESULTS
Patient characteristics
From the 9423 patients in the METEOR registry who
were eligible for inclusion in the current study, 5230
patients who had started treatment with a first TNFi
had sufficient data to be included in the analyses.
A flow chart of the patient selection process and baseline
characteristics of included and non-included patients is
available in supplementary file 1. Most baseline charac-
teristics were similar between the included and non-
included patients. Only the percentage of never smokers
was higher in the included patients, and the country of
inclusion differed for the included and non-included
patients.
Baseline characteristics of patients starting their first
TNFi per BMI category are presented in table 1. Most
patients had a normal weight (46%) or had pre-obesity
(32%). Four per cent of patients were underweight and
18% of patients belonged to one of the three obesity
categories. All patients were bionaïve at the start of their
first TNFi.
Patients in the underweight category were more often
female and were younger. The percentage of current
smokers decreased with increasing BMI category. Disease
activity as measured by DAS28 was lowest in underweight
Rheumatoid arthritis
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patients and highest in obesity class III patients. This was
mainly caused by differences in ESR and in VAS scores for
patient global health.
For the analyses regarding the first course of each TNFi
separately, data were available from 2069 patients starting
adalimumab, 263 patients starting certolizumab, 2936
patients starting etanercept, 84 patients starting golimu-
mab and 1390 patients starting infliximab (table 2).
Ninety-one per cent of the patients starting infliximab
were bionaïve, compared with 76% of the patients start-
ing etanercept and 78% of the patients starting adalimu-
mab. Patients starting golimumabmore often had obesity
and patients starting certolizumab were more often
underweight. Moreover, patients starting golimumab
were more often male patients from the USA or the
Netherlands and they were less often current smokers,
with shorter symptom duration and slightly lower disease
activity. Other patient characteristics were similar
between the different TNFi.
BMI category and treatment failure during the total follow-up
The Kaplan–Meier curve in figure 1 shows the crude
association between the different BMI categories and
overall drug survival in patients starting their first TNFi.










n=153 n=1897 n=1332 n=528 n=142 n=64
BMI, kg/m2 17.4 (1.0) 22.4 (1.7) 27.2 (1.4) 32.0 (1.4) 37.0 (1.4) 43.4 (3.0)
Weight, kg 47.1 (5.7) 60.2 (7.8) 73.3 (9.0) 84.8 (9.8) 96.0 (12.2) 111.4 (12.6)
Gender, % female 94.1 84.7 74.7 80.9 88.7 90.5
Age at start of TNFi, years 46 (16) 53 (13) 56 (11) 55 (11) 55 (11) 54 (10)
RF, % 76.9 78.6 76.0 78.2 75.0 73.8
ACPA, % 73.4 77.8 74.8 74.6 70.8 71.7
Smoking, %
Never 30.5 42.3 52.9 64.1 69.4 69.8
Current 57.6 44.2 31.9 19.7 14.3 13.2
Stopped 11.9 13.5 15.2 16.2 16.3 17.0
Symptom duration at
starting TNFi, years
7.3 (3.4; 14.9) 8.2 (4.3; 14.9) 9.0 (4.3; 16.3) 7.7 (4.0; 13.9) 8.7 (3.6; 16.8) 7.0 (3.4; 13.9)
DAS28 4.8 (1.6) 4.9 (1.6) 5.0 (1.6) 5.2 (1.6) 5.1 (1.6) 5.6 (1.7)
ESR 31 (24) 32 (24) 31 (23) 34 (24) 34 (23) 40 (28)
CRP 6.8 (1.3; 17) 5.7 (2; 17) 7.2 (3; 18) 8.1 (3; 19.9) 8.7 (4.4; 20) 11 (3.8; 21)
VAS patient global health 51 (24.5; 70) 55 (30; 75) 55 (33; 75) 56 (38; 78) 60 (40; 80) 70 (51; 80)
VAS patient pain 51 (30; 75) 60 (34; 77) 56 (39; 77) 60 (33; 80) 59 (35; 80) 65 (40; 80)
TJC28 7 (2; 12) 6 (2; 12) 6 (2; 12) 7 (2; 14) 6 (1; 12) 7.5 (1; 17)
SJC28 3 (1; 8) 4 (1; 10) 4 (1; 9) 4 (1; 8) 4 (1; 8) 4 (1.5; 8.5)
Country distribution, %
Italy 72.6 56.7 42.6 30.3 21.1 9.4
Portugal 7.2 19.4 28.8 33.9 28.9 31.3
Netherlands 8.5 11.8 12.4 11.4 9.2 9.4
USA 0 5.0 8.4 11.2 23.2 29.7
UK 3.3 1.4 2.8 5.9 5.6 10.9
Japan 3.3 2.4 0.8 0.2 0.0 0.0
Mexico 1.3 0.8 1.2 3.8 2.8 4.7
France 1.3 1.3 1.1 0.2 1.4 1.6
Qatar 0.7 0.7 0.7 1.3 4.2 3.1
Other 1.8 0.5 1.2 1.8 3.6 0
Table based on non-imputed data. Weight was available for all patients, BMI was missing in 19% of patients. Data are presented as mean (SD),
median (IQR) or %.
ACPA, anti-citrullinated protein antibodies; BMI, bodymass index; CRP, C reactive protein; country, country in which the patient is treated; DAS,
disease activity score; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; TJC, tender joint count; TNFi, tumour necrosis factor
inhibitor; SJC, swollen joint count; VAS, visual analogue scale.
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Over the total follow-up duration of a maximum of
5000 days (approximately 13.5 years), 72% of patients
stopped their TNFi. Of these, a limited number of
patients had a short treatment stop of <2 months: n=8
for etanercept and infliximab, n=1 for adalimumab and
certolizumab, and n=0 for golimumab. Patients in the
normal weight and pre-obesity categories had the longest
drug survival and patients in obesity class II and III the
shortest drug survival. Especially patients in obesity class
III had shorter drug survival than patients from the other
Table 2 Baseline characteristics per TNFi
All first TNFi Adalimumab Certolizumab Etanercept Golimumab Infliximab
n=5230 n=2069 n=263 n=2936 n=84 n=1390
BMI, kg/m2 25.8 (5.0) 25.6 (5.0) 25.7 (5.2) 25.7 (5.0) 28.5 (6.1) 25.8 (5.0)
BMI category, %
Underweight 3.7 3.7 6.3 3.8 2.5 3.5
Normal weight 46.1 48.1 50.2 47.0 28.4 44.8
Pre-obesity 32.4 31.3 26.8 31.4 33.3 33.1
Obesity class I 12.9 11.9 12.7 12.9 21.0 13.9
Obesity class II 3.5 3.0 2.4 3.5 7.4 3.2
Obesity class III 1.6 1.8 1.5 1.4 7.4 1.6
Weight, kg 68.2 (14.8) 68.2 (14.6) 68.7 (14.6) 67.8 (15.0) 78.2 (18.0) 66.8 (14.2)
Female, % 81.6 83.3 80.2 81.3 71.4 82.2
Age at start of TNFi, years 54 (13) 53 (12) 51 (14) 54 (13) 54 (13) 53 (13)
RF, % 78.1 76.4 73.6 79.8 72.0 79.8
ACPA, % 76.2 75.9 72.8 76.8 69.3 78.1
Smoking, %
Never 47.8 46.2 33.6 48.3 48.5 47.1
Current 38.5 40.7 50.5 37.6 29.4 41.5
Stopped 13.6 13.1 15.9 14.1 22.1 11.5
Symptom duration at start
of TNFi, years
8.3 (4.1; 15.5) 7.9 (4.1; 15.2) 7.8 (4.1; 14.6) 8.2 (3.9; 15.0) 6.7 (3.8; 11.6) 8.3 (4.1; 16.3)
DAS28 5.1 (1.6) 5.0 (1.6) 4.8 (1.3) 5.0 (1.6) 4.5 (1.6) 5.5 (1.5)
ESR 33 (23) 32 (23) 30 (23) 34 (24) 30 (24) 39 (25)
CRP 7 (2.4; 21) 6.7 (2; 18.7) 55. (1.7; 15.5) 7 (2.3; 20) 5.9 (1.5; 15.6) 8.6 (3; 32)
VAS patient global health 57 (35; 75) 55 (34; 75) 60 (40; 80) 57 (33; 77) 50 (32.5; 70) 62 (47; 80)
VAS patient pain 60 (40; 80) 60 (40; 80) 60 (41; 80) 60 (40; 80) 58 (27; 75) 64 (49; 80)
TJC28 6.5 (2; 13) 6 (2; 12) 5 (2; 10) 6 (2; 12) 3 (0.5; 9.5) 9 (4; 14)
SJC28 5 (1; 10) 4 (1; 9) 4 (1.5; 7) 4 (1; 9) 2 (0; 7) 7 (2; 12)
Country, %
Italy 55 57 71 53 0 67
Portugal 21 18 0 22 0 24
Netherlands 10 13 21 9 44 4
USA 6 7 2 7 38 3
UK 2 2 1 3 0 0
Japan 2 0 0 3 0 1
Mexico 1 1 1 1 4 0
France 1 1 1 1 0 0
Qatar 1 1 1 1 0 0
Other 1 0 2 0 18 1
Table based on non-imputed data. Data are presented as mean (SD), median (IQR) or %.
ACPA, anti-citrullinated protein antibodies; BMI, bodymass index; country, country in which the patient is treated; CRP, C reactive protein; DAS,
disease activity score; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; TNFi,
tumour necrosis factor inhibitor; VAS, visual analogue scale.
Rheumatoid arthritis
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BMI categories. Reasons for treatment failure were una-
vailable, but themean (SD) DAS28 at the final visit before
stopping treatment was 3.9 (1.6), supporting the assump-
tion that most patients stop treatment because of
ineffectiveness.
Results from fully adjusted Cox regression analyses
based on the imputed data set support these findings,
with statistically significantly shorter drug survival for
patients in obesity class III (HR 1.67, 95% CI 1.29 to
2.18) and obesity class II (HR 1.28, 95% CI 1.06 to
1.54), but also for patients in the underweight category
(HR 1.3, 95% CI 1.07 to 1.58), compared with patients in
the normal weight category (table 3). We observed no
statistically significant effect modification by baseline
Table 3 Results of the Cox regression analyses to assess the association between BMI category and drug survival per TNFi
Adjusted
HR (95% CI) P value
Crude
HR (95% CI) P value
Time on treatment
(months) median (IQR)
All TNFi 34.8 (12.6; 72.1)
BMI category
Underweight 1.3 (1.07; 1.58) 0.011 1.2 (0.97; 1.44) 0.091 32.6 (9.4; 59.4)
Normal weight Ref Ref 34.9 (12.4; 72.3)
Pre-obesity 0.97 (0.89; 1.05) 0.451 1.0 (0.95; 1.12) 0.471 34.9 (12.9; 71.7)
Obesity class I 1.09 (0.97; 1.21) 0.145 1.2 (1.06; 1.31) 0.003 34.7 (12.3; 73.6)
Obesity class II 1.28 (1.06; 1.54) 0.012 1.4 (1.16; 1.68) <0.001 29.7 (10.3; 50.8)
Obesity class III 1.67 (1.29; 2.18) <0.001 1.9 (1.44; 2.42) <0.001 21.1 (9.7; 43.0)
Adalimumab 26.8 (10.3; 60.6)
BMI category
Underweight 1.2 (0.84; 1.58) 0.366 1.01 (0.79; 1.46) 0.640 20.5 (5.9; 58.2)
Normal weight Ref Ref 24.0 (9.7; 56.0)
Pre-obesity 0.86 (0.75; 0.99) 0.036 0.92 (0.81; 1.05) 0.233 32.5 (12.2; 67.9)
Obesity class I 0.91 (0.75; 1.10) 0.309 1.02 (0.85; 1.21) 0.865 27.1 (9.0; 64.4)
Obesity class II 1.21 (0.88; 1.67) 0.234 1.33 (0.97; 1.82) 0.076 26.2 (11.3; 47.0)
Obesity class III 1.31 (0.87; 1.97) 0.192 1.52 (1.03; 2.23) 0.034 16.5 (6.2; 62.0)
Certolizumab Number of patients per group too small 10.5 (3.7; 18.3)
Etanercept 29.5 (11.2; 60.0)
BMI category
Underweight 1.05 (0.80; 1.38) 0.734 0.99 (0.76; 1.29) 0.919 38.3 (12.3; 59.5)
Normal weight Ref Ref 31.9 (12.0; 64.4)
Pre-obesity 1.01 (0.90; 1.14) 0.820 1.07 (0.96; 1.19) 0.254 30.5 (11.3; 60.5)
Obesity class I 1.13 (0.97; 1.32) 0.108 1.25 (1.09; 1.45) 0.002 30.2 (11.5; 62.7)
Obesity class II 1.27 (0.98; 1.65) 0.069 1.33 (1.04; 1.70) 0.024 22.4 (5.5; 47.3)
Obesity class III 1.79 (1.25; 2.55) 0.001 1.93 (1.36; 2.74) <0.001 20.2 (4.0; 49.1)
Golimumab Number of patients per group too small 12.0 (4.7; 28.0)
Infliximab 34.9 (12.5; 77.8)
BMI category
Underweight 1.82 (1.20; 2.76) 0.005 1.66 (1.11; 2.48) 0.014 25.8 (6.2; 44.5)
Normal weight Ref Ref 37.0 (11.1; 78.4)
Pre-obesity 0.96 (0.80; 1.16) 0.685 1.02 (0.86; 1.21) 0.840 32.3 (13.7; 84.1)
Obesity class I 1.21 (0.96; 1.53) 0.115 1.29 (1.03; 1.61) 0.027 27.8 (10.5; 69.3)
Obesity class II 1.49 (0.98; 2.26) 0.064 1.71 (1.14; 2.55) 0.009 19.3 (11.4; 37.8)
Obesity class III 1.46 (0.79; 2.71) 0.225 1.81 (1.01; 3.23) 0.045 27.7 (13.1; 34.0)
Cox regression analyses results based on multiply imputed data. Adjusted analyses were corrected for gender, smoking, age, baseline DAS28
and GC use. Before imputation, the proportion of missing data was 19% for BMI, 0.2% for gender, 0.3% for age, 49% for smoking and 18% for
baseline DAS28. Increased HR indicates a higher hazard to stop medication. Time on treatment is the crude time on treatment, with follow-up
time censored at 5000 days.
BMI, body mass index; DAS, disease activity score; GC, glucocorticoid; TNFi, tumour necrosis factor inhibitor.
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pain category (p=0.725), indicating that the association
between BMI and drug survival was similar in patients
reporting different levels of pain. However, we did
observe that the last measured DAS28 before stopping
treatment was higher for patients in higher BMI cate-
gories (table 5). After adjustment, this association
remained significant for obesity category II (p=0.025)
and obesity category III (p=0.032), indicating that for
patients in the highest BMI categories, the decision to
stop treatment was made at higher disease activity levels.
Analyses for the individual bDMARDs were only per-
formed for adalimumab, etanercept and infliximab,
because the number of patients per BMI category were
too small for certolizumab and golimumab. In figure 2,
the Kaplan–Meier curves are presented for the crude
association between the different BMI categories and
drug survival in patients starting adalimumab, etanercept
and infliximab. Seventy per cent of patients on adalimu-
mab stopped their treatment during 5000 days of follow-
up, and 74% of patients on etanercept and infliximab
stopped their treatment. For all three drugs, obese
patients had shorter drug survival, although we observed
slight differences between the different TNFi. For adali-
mumab, patients from obesity class II and III showed
shorter drug survival. For etanercept, patients from all
three obesity classes showed shorter drug survival, with
shortest drug survival for patients from obesity class III.
For infliximab, patients with a normal weight or pre-
obesity had longest drug survival, and patients from obe-
sity class II and III and also underweight patients had
shortest drug survival. However, it must be noted that in
the obesity class III category, the number of patients on
infliximab was limited (n=15 in the non-imputed
database).
Numerically, these results were supported by the out-
comes of the adjusted Cox regression analyses based on
the imputed database, although not all of these aforemen-
tioned effects reached statistical significance (table 3).
With normal weight patients as the reference category,
we observed a statistically significantly longer drug survival
for patients in the pre-obesity category starting adalimu-
mab (HR 0.86, 95% CI 0.75 to 0.99). For etanercept, we
observed a statistically significantly shorter drug survival
for patients in obesity class II (HR 1.27, 95% CI 0.98 to
1.65) and obesity class III (HR 1.79, 95% CI 1.25 to 2.55).
For infliximab, we observed a statistically significantly
shorter response for patients from the underweight (HR
1.82, 95% CI 1.20 to 2.76) and obesity class II categories
(HR 1.49, 95% CI 0.98 to 2.26).
For none of these drugs, statistically significant effect
modification by pain category was observed (adalimumab
p=0.849, etanercept p=0.984, infliximab p=0.598), indicat-
ing that the differences in the association between BMI
category and drug survival for patients with different
reported pain levels were not dependent on those reported
pain levels.
BMI category and treatment failure during the first year of
follow-up
Next, we limited our analysis to the first year of follow-up,
to investigate the association between BMI category and
primary treatment failure. Overall, the Kaplan–Meier
curve in figure 2, with follow-up duration limited to
1 year, shows similar results as in figure 1, with shortest
Figure 2 Kaplan–Meier curves for the association between BMI category and drug survival in patients starting TNFi during the
first year of follow-up. (A) Data of all patients starting their first TNFi. Data for patients starting adalimumab (B), etanercept (C) and
infliximab (D) are shown separately. Kaplan–Meier curves are based on non-imputed and non-adjusted data.
BMI, body mass index; TNFi, tumour necrosis factor inhibitor.
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drug survival duration for patients from obesity class III.
However, there is also a shorter drug survival for under-
weight patients. For etanercept and infliximab, also
mainly a shorter drug survival for patients in obesity
class III was observed. For adalimumab during the
first year of follow-up, no major differences between the
different weight categories were seen.
After adjustment for potential confounders in the Cox
regression analyses (table 4), we found statistically
significant differences in drug survival (for all TNFi com-
bined) in the underweight patients (shorter drug survival
(HR 1.37, 95% CI 1.01 to 1.86) compared with normal
weight patients) and in patients with pre-obesity (longer
drug survival (HR 0.85, 95% CI 0.74 to 0.99). For etaner-
cept, patients from obesity class II and III had statistically
significantly shorter drug survival (obesity class II (HR
1.64, 95% CI 1.11 to 2.42) and obesity class III (HR 2.23,
95% CI 1.33 to 3.76)). For adalimumab, underweight
Table 4 Results of the Cox regression analyses to assess the association between BMI category and drug survival per TNFi
within 1 year of follow-up
Adjusted
HR (95% CI) P value
Crude
HR (95% CI) P value
All TNFi
BMI category
Underweight 1.37 (1.01; 1.86) 0.044 1.30 (0.96; 1.77) 0.085
Normal weight Ref Ref
Pre-obesity 0.85 (0.74; 0.99) 0.038 0.89 (0.77; 1.03) 0.126
Obesity class I 1.00 (0.83; 1.22) 0.975 1.09 (0.90; 1.32) 0.359
Obesity class II 1.14 (0.83; 1.57) 0.408 1.25 (0.91; 1.71) 0.163
Obesity class III 1.40 (0.92; 2.15) 0.118 1.60 (1.05; 2.44) 0.027
Adalimumab
BMI category
Underweight 1.58 (1.03; 2.42) 0.037 1.41 (0.92; 2.14) 0.112
Normal weight Ref Ref
Pre-obesity 0.67 (0.53; 0.85) 0.001 0.72 (0.57; 0.90) 0.003
Obesity class I 0.81 (0.60; 1.11) 0.191 0.91 (0.67; 1.22) 0.519
Obesity class II 0.91 (0.54; 1.55) 0.733 1.01 (0.60; 1.71) 0.958
Obesity class III 0.87 (0.43; 1.77) 0.695 0.95 (0.47; 1.92) 0.881
Certolizumab Number of patients per group too small
Etanercept
BMI category
Underweight 0.99 (0.62; 1.59) 0.976 1.04 (0.67; 1.61) 0.862
Normal weight Ref Ref
Pre-obesity 1.05 (0.86; 1.27) 0.653 1.04 (0.86; 1.25) 0.714
Obesity class I 1.17 (0.90; 1.51) 0.234 1.22 (0.96; 1.55) 0.104
Obesity class II 1.64 (1.11); 2.42) 0.014 1.51 (1.03; 2.22) 0.034
Obesity class III 2.23 (1.33; 3.76) 0.003 2.41 (1.46; 4.00) 0.001
Golimumab Number of patients per group too small
Infliximab
BMI category
Underweight 1.50 (0.78; 2.90) 0.225 1.46 (0.78; 2.73) 0.232
Normal weight Ref Ref
Pre-obesity 0.87 (0.63; 1.20) 0.393 0.90 (0.66; 1.22) 0.501
Obesity class I 1.21 (0.82; 1.78) 0.338 1.29 (0.89; 1.87) 0.172
Obesity class II 1.01 (0.48; 2.09) 0.989 1.17 (0.59; 2.31) 0.653
Obesity class III 1.74 (0.75; 4.07) 0.199 2.16 (1.00; 4.64) 0.049
Cox regression analyses results based on multiply imputed data. Adjusted analyses were corrected for gender, smoking, age, baseline DAS28
and GC use. Increased HR indicates a higher hazard to stop medication.
BMI, body mass index; DAS, disease activity score; GC, glucocorticoid; TNFi, tumour necrosis factor inhibitor.
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patients had statistically significantly shorter drug survival
(HR 1.58, 95% CI 1.03 to 2.42) and patients with pre-
obesity had statistically significantly longer drug survival
(HR 0.67, 95%CI 0.53 to 0.85). For infliximab, we did not
observe any statistically significant difference, possibly
due to relatively limited patient numbers.
DISCUSSION
In this large real-life observational registry with long-term
follow-up, we found that patients with RA who were
underweight and in obesity class II (BMI between 35
and 40 kg/m2) and III (BMI>40 kg/m2) had shorter
drug survival on TNFi, with the strongest effect for
patients from obesity class III. This association was not
related to levels of reported pain, as has been previously
suggested.11 Furthermore, this is the first study investigat-
ing drug survival for different TNFi separately. We inves-
tigated adalimumab, etanercept and infliximab
individually and observed that underweight patients
mainly had a worse response to infliximab, whereas the
relationship between obesity classes and drug survival
seemed less strong for adalimumab than for etanercept
and infliximab.
Primary failure or delayed failure after initial good
response may occur through different mechanisms and
we therefore also investigated the association between
BMI category and treatment failure during the first year
after TNFi initiation. Overall, we found similar results, with
shortest TNFi survival in obesity class III, but not for adali-
mumab, and for underweight patients, but not for etaner-
cept. In general, BMI appears to be associated with
(chance of) clinical response (levels) in RA.8 9 Whether
there is an association between response to treatment with
specifically TNFi and BMI, and if so, through what
mechanism, has been the subject of several studies in RA,
as well as in other areas of TNFi use.12 18 20 27 Most of these
previous studies in RA have chosen composite disease
activity measures such as the DAS28 as outcome variable.
However, interpretation of composite disease activity
measures may be challenging in patients with obesity.
The examination of joint swelling may be more difficult,
and ESR and reported pain levels are expected to be
higher.23 24 28 29 To combine disease activity measure-
ments with ‘soft’ outcomes that steer treatment deci-
sions, we have chosen to study treatment survival to
investigate whether differences in BMI were indeed asso-
ciated with stopping treatment more often.
One previous smaller study has also reported that drug
survival was shorter in obese patients with RA starting
TNFi, although differences between the three defined
BMI categories were not statistically significant.12 In con-
trast, another large observational study concluded that
obesity was not associated with treatment discontinuation
in patients with RA starting TNFi.18 However, in that
study, results were adjusted for several comorbidities,
such as diabetes and hypertension. As it may be argued
that these factors exert their effect on drug survival to
a large extent through the causal pathway between BMI
and drug survival, considering these factors as potential
confounders is incorrect and would obscure an associa-
tion between BMI and drug survival. Neither study strati-
fied for the various TNFi types.
We looked at drug survival as proxy for (duration of)
clinical response, but drug survival may also be deter-
mined by costs, clinical remission (less likely a reason
in year 1 after treatment start), occurrence of side effects
or comorbidities (including pain-related comorbidities),
some of which may also increase the DAS, or otherwise by
wish of the patient. In the current study, we could not
stratify between the different reasons for stopping the
treatment. However, as the DAS28 at the final visit before
stopping the treatment was high, it is likely that drug
survival was mainly determined by treatment failure.
Table 5 Results of the linear regression analyses to assess the association between BMI category and DAS28 at the final visit
before stopping TNFi
Adjusted
HR (95% CI) P value
Crude





Underweight −0.25 (−0.51; 0.0091) 0.059 −0.27 (−0.55; −0.00017) 0.050 3.4 (1.5)
Normal weight Ref Ref 3.8 (1.6)
Pre-obesity 0.092 (−0.024; 0.21) 0.120 0.076 (−0.042; 0.19) 0.207 3.9 (1.6)
Obesity class I 0.13 (−0.028; 0.29) 0.106 0.20 (0.039; 0.36) 0.015 4.1 (1.6)
Obesity class II 0.31 (0.039; 0.59) 0.025 0.38 (0.098; 0.67) 0.009 4.2 (1.6)
Obesity class III 0.45 (0.039; 0.87) 0.032 0.65 (0.22; 1.08) 0.003 4.6 (1.7)
Mean (SD) DAS based on non-imputed data. Median (IQR) time between the final available DAS28 and stopping treatment with the TNFi was 0.9
(0.0; 5.2) months.
Linear regression analyses are based on multiply imputed data. Adjusted analyses were corrected for gender, smoking, age, baseline DAS28
and GC use.
BMI, body mass index; DAS, disease activity score; GC, glucocorticoid; TNFi, tumour necrosis factor inhibitor.
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It has been hypothesised that the association between
BMI and treatment response is a result of inflammatory
pathways that are active in excess adipose tissue.4–7 Also,
a relation between higher bodyweight and accelerated
clearance of monoclonal antibodies such as TNFi has
been suggested, although the mechanism remains uncer-
tain, and possibly vary per drug.8 30
Alternatively, it has been suggested that RA patients in
higher BMI categories report more pain and are more
often diagnosed with chronic pain syndrome and osteoar-
thritis, which may increase disease activity measures and
may therefore influence treatment response.11 23–26 31 In
the current study, we assessed whether the association
between BMI category and drug survival was different
for patients indicating different baseline levels of pain,
but we observed similar effects in all pain categories.
Therefore, it seems unlikely that differences in pain can
explain the association between BMI and treatment
response. We did observe that disease activity measured
with DAS28 before stopping the TNFi was higher with
increasing BMI category, suggesting that besides the
DAS28, additional reasons influence shared decision-
making processes between rheumatologist and patient
that ultimately determine TNFi survival.
Noneof thepreviously published studies into the relation-
ship between BMI and treatment outcomes in RA used the
BMI categories as defined by the WHO, and patients with
RAbeing underweight are rarely studied. Lowbodyweight is
increasingly rare and possibly in relation to a focus on
effects of obesity, underweight patients are often grouped
with normal weight patients in the comparator group.1 9
Our data show that underweight patients are a neglected
group that may require customised treatment and may also
help to shed light on the relation between bodyweight and
treatment outcomes, because the strongest effects are
observed in the underweight and themore extreme obesity
categories. This is in accordance with a previous study in
patients with Crohn’s disease starting infliximab therapy,
which also found worse disease outcomes at the under-
weight and the most extreme obese categories.10
A limited number of Asian patients were included in
the current study. It has been previously suggested that
the cut-off points for BMI categories should be adjusted
for Asian populations, since health risks in these popula-
tions may occur at a lower BMI than in other populations.
We have followed the current advice of the WHO and
used the international classification for BMI categories
for all included patients.19 To what extent BMI correctly
reflected differences in fat mass and lean body mass in all
patients cannot be determined based on our data.
We observed slight differences between the various TNFi
with a stronger association between BMI and drug survival
in patients with RA starting infliximab, as was previously
observed, but also in patients starting etanercept compared
with patients starting adalimumab.7 Underweight patients
mainly had a shorter drug survival on infliximab, and dur-
ing the first year of follow-up also on adalimumab. This
does not seem to be related to the mode of administration,
as infliximab is given intravenously in a weight-based dose
and both etanercept and adalimumab are administered
subcutaneously in a fixed dose. Several studies in other
rheumatic diseases also studied the association between
BMI and treatment response in different TNFi, but results
were inconsistent and even opposite between studies and
underweight patients were not previously studied.7 32–37
The reason for this difference between different TNFi is
yet unclear and requires further study.
As our data are daily practice based, our results may be
affected by bias, including bias in treatment decision-
making and bias due to missing data. We performed multi-
ple imputation in an attempt to prevent bias due to missing
data and we have adjusted our analyses for several potential
confounders to reduce the risk of confounding by indica-
tion, but a risk of residual bias should always be considered.
Despite performing separate analyses for three different
TNFi, we did not perform an adjustment for multiple
testing and therefore it is possible that some of the
observed effects are statistically significant by chance. How-
ever, if we would have performed a Bonferroni correction
and would have used a p value of 0.017 (=0.05/3), most
effects would still be significant and only the observed
longer drug survival for pre-obesity patients on adalimu-
mab would not be significant anymore.
Another factor that could influence TNFi survival is the
number of previous bDMARDs used. For our first analysis
in which we assessed all TNFi combined, all patients were
bionaïve. For analyses on the infliximab, etanercept and
adalimumab separately, up to 24% of patients had used
a previous bDMARD. However, we did not aim to com-
pare retention of the different bDMARDs, but we rather
aimed to compare the association between BMI cate-
gories and drug survival for the different TNFi. As we
did not observe an association between BMI and the
number of previous bDMARDs, the number of previous
bDMARDs was not considered a potential confounder.
Overall, we included a large number of patients. How-
ever, for the analyses of the different TNFi, patient num-
bers were smaller for the lowest and highest BMI
categories. Therefore, the power to detect differences
between the groups may has been limited, especially for
infliximab. Especially for longer follow-up, this may have
introduced a risk of overfitting. To limit this risk, we have
censored follow-up at 5000 days.
In conclusion, we found shorter treatment survival for
underweight patients with RA having a BMI <18.5 kg/m2
and for obese patients with RA having a BMI >30 kg/m2
who started treatment with TNFi in a large international
registry based on real-life data. This effect seemed strongest
for patients from obesity class III (BMI>40 kg/m2), who
showed shorter treatment survival already early during fol-
low-up. When independently assessing these effects for
infliximab, adalimumab and etanercept, the effect in
underweight patients was mainly observed for infliximab
and during the first year of follow-up also for adalimumab,
whereas the effect in obese patients wasmainly observed for
infliximab and etanercept. What determines these
RMD Open
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associations remains unclear, and whether interventions to
stimulate weight loss for instance could lead to a better
treatment response to TNFi in obese patients, as has been
previously shown in psoriatic arthritis patients, remains to
be elucidated.38
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